Italian guidelines on thrombolysis indications in ischemic stroke have been revised after IST-3 trial and Cochrane revision: Cons

Internal and Emergency Medicine

Volumn 8, Issue 8, 2013, Pages 651-652

  Costantino, Giorgio ^a   Podda, Gian Marco ^c   Bonzi, Mattia ^a   Sbrojavacca, Rodolfo ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN ISCHEMIA; COMPLICATION; FIBRINOLYTIC THERAPY; HUMAN; ITALY; LITERATURE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE;

BRAIN ISCHEMIA; HUMANS; ITALY; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVIEW LITERATURE AS TOPIC; STROKE; THROMBOLYTIC THERAPY;

EID: 84888292767     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-013-0986-y     Document Type: Editorial

References (14)

1. Sackett DL, Rosenberg WMC, Muir Gray JA et al (1996) Evidence based medicine: what it is and what it isn't. BMJ 312: 71-72.
2. Guyatt GH, Sackett DL, Cook DJ (1993) Users' guides to the medical literature: II. How to use an article about therapy or prevention: A. Are the results of the study valid? JAMA 270(21): 2598-2601.
3. SPREAD Italian National Guidelines for Stroke (2012) http://www. spread. it. Accessed 5 May 2013.
4. IST-3 collaborative group (2012) The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 379(9834): 2352-2363. doi: 10. 1016/S0140-6736(12)60768-5.
5. Leys D, Cordonnier C (2012) rt-PA for ischaemic stroke: what will the next question be? Lancet 379(9834): 2320-2321.
6. Hoffman JR, Cooper RJ (2012) How is more negative evidence being used to support claims of benefit: The curious case of the third international stroke trial (IST-3). Emerg Med Australas 24: 473-476.
7. Fatovich DM (2012) Believing is seeing: stroke thrombolysis remains unproven after the third international stroke trial (IST-3). Emerg Med Australas 24: 477-479.
8. Cenciarelli S, Mazzoli T, Ricci S (2013) Ischaemic stroke and thrombolysis: ask the onset time, not the age! Intern Emerg Med 8: 99-100. doi: 10. 1007/s11739-012-0879-5.
9. Del Medico M, Bonura A, Gruppo di Autoformazione Metodologica (GrAM) (2013) Can we extend thrombolysis indications for acute ischaemic stroke? The IST-3 study. Intern Emerg Med 8(3): 261-262.
10. Radecki RP, Chathampally YG, Press GM (2013) rt-PA and stroke: does IST-3 make it all clear or muddy the waters? Answers to the November 2012 Journal Club questions. Ann Emerg Med 61(4): 489-498.
11. Rui Wang MS, Lagakos SW, Ware JH et al (2007) Statistics in medicine-reporting of subgroup analyses in clinical trials. NEJM 357: 2189-2194.
12. ISIS-2 (Second International Study of Infarct Survival) (1988) Collaborative Group Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17, 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2: 349-360.
13. Wardlaw JM, Murray V, Berge E et al (2012) Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 379(9834): 2364-2372.
14. Costantino G, Rusconi AM, Duca PG et al (2009) Eligibility criteria in heart failure randomized controlled trials: a gap between evidence and clinical practice. Intern Emerg Med 4(2): 117-122.